CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

James Mock

Chief Financial Officer, Moderna

Verified interview transcripts, podcast appearances, and direct quotes from James Mock, Chief Financial Officer at Moderna. AI-verified speaker identity with full-text searchable transcripts.

Recent appearances

  • Moderna (MRNA) CFO on Earnings & Outlook

    May 02, 2024 · 📺 Schwab Network

    Moderna’s (MRNA) adjusted EPS came in at -$3.07 versus an estimated -$3.59 and revenue came in at $167.00M versus an estimated $124.74M. CFO Jamey Mock joins Oliver Renick to discuss Moderna’s 1Q earnings and the outlook for the company. He also talks about Moderna’s product pipeline. Tune in to find out more about the stock market today. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-... Download the Amazon Fir…

    Watch on YouTube ↗

  • Moderna's CFO on How to Allocate Capital in Big Pharma | Odd Lots

    March 11, 2024 · 📺 Bloomberg Podcasts

    The pharmaceutical space is characterized by extreme uncertainty. You never know what drugs are going to pan out. The lead time for development is extremely long. Market size is inherently unknowable. And the regulatory and pricing climate is constantly changing. So, how does a company decide where to invest its cash? On this episode, we speak with Moderna's chief financial officer, Jamey Mock, about how he views the problem. He explains the process by which the vaccine maker chooses which bets to make, how changing fortunes within the stock market affect corporate decision-making and the role…

    Watch on YouTube ↗

  • Moderna (MRNA) CFO on Earnings & Covid Vaccine Sales

    February 22, 2024 · 📺 Schwab Network

    Moderna (MRNA) expects regulatory approval for its investigational RSV vaccine for older adults starting in 1H24. Moderna CFO Jamey Mock discusses 4Q earnings, as well as Covid vaccine sales. Moderna has reaffirmed its 2024 product sales outlook. Tune in to find out more about the stock market today. #investing #trading #finance #stocks #global #equities #markets #stockmarket #stockmarkettoday #moderna #mrnastock

    Watch on YouTube ↗

  • The Mentoring Round Jamey Mock, CFO, Moderna

    January 12, 2024 · 📺 CFO THOUGHT LEADER

    ... through those two to five year time period Jamie mock thank you for joining us on CFO thought leader thank you so much Jack.

    Watch on YouTube ↗

  • 963: How a Biotech Disrupter is De-risking R&D | Jamey Mock, CFO, Moderna

    January 07, 2024 · 📺 CFO THOUGHT LEADER

    It’s no secret that Moderna’s R&D efforts have expanded well beyond the realm of COVID-19. CFO Jamey Mock tells us that today the company has more than 40 drugs in its pipeline, with targets such as respiratory, late-stage, oncological, and rare diseases. As he explains, this diversity means that the biotech innovator is reliant not solely on one product or therapeutic area, which makes for less risk than would be the case if the company had only a single product focus. Meanwhile, Mock leaves little doubt that the finance function is not excluded from the firm’s appetite for innovation…

    Watch on YouTube ↗

  • Moderna (MRNA) CFO On Covid Vaccine Demand & Earnings

    November 02, 2023 · 📺 Schwab Network

    Moderna (MRNA) posts a wider loss and cuts guidance as Covid vaccine sales drop. Its adjusted EPS came in at -$9.53 versus an estimated -$2.01 and revenue came in at $1.83B versus an estimated $1.33B. Moderna CFO Jamey Mock joins Oliver Renick to give an overview of the company. He talks about how MRNA sees at least $6B of Covid-19 vaccine sales in 2023. MRNA expects 50M doses in the U.S. this fall, which was previously estimated at 50M-100M doses. Mock then goes over what’s in the pipeline for MRNA. Tune in to find out more about the stock market today. #investing #trading #finance #stocks…

    Watch on YouTube ↗

  • Moderna CEO discusses earnings and how the company aims to break even by 2026

    November 02, 2023 · 📺 Yahoo Finance

    While boasting a third-quarter revenue beat, biotech firm Moderna (MRNA) reported an overwhelmingly higher-than-expected loss of $9.53 per share. Its shares find themselves under pressure over weakening COVID-19 vaccine demand. Moderna's Chief Financial Officer Jamey Mock joins Yahoo Finance’s Anjalee Khemlani to discuss the company’s forward strategy. Mock notes that the company aims to "break-even by 2026," acknowledging investors' concerns. Mock’s optimism for the 2026 deadline is based on "organic growth opportunity” in the late-stage product pipeline with plans to introduce RSV and flu va…

    Watch on YouTube ↗

Other executives at Moderna

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →